#### **PATENT**

TECH CENTER 1600/2900

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

JAN 2 4 2002

Small, Kersten M. et al.

Examiner: Unassigned

Serial No.:

09/636,259

1655 Group Art Unit:

Filed:

August 10, 2000

Docket: 13092

For:

Alpha-2A-adrenergic receptor polymorphisms

Kalow & Springut LLP

488 Madison Avenue, 19th Floor New York, New York 10022

Dated: January 3, 2002

**Assistant Commissioner for Patents** Washington, D.C. 20231

## REPLY TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO **ACID SEQUENCE DISCLOSURES**

Sir:

This is a reply to the Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures issued in connection with the above-identified patent application on December 3, 2001. The deadline for reply to this Notice is January 3, 3002. Accordingly, this reply is timely filed.

Please amend the above-identified application as follows:

### IN THE SPECIFICATION:

After the Figures, please remove the initial sequence listing, and insert the attached substitute sequence listing.

Certificate of Mailing Under 37 C.F.R. 1.8

I hereby declare that this correspondence is being deposited with the United States Postal Service first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C.

/02 Name:\_



Applicant: Small et al. Serial No. 09/636,259 Docket: 13092

#### **REMARKS**

The Examiner objects to the initial sequence listings submitted August 10, 2000. Applicants by this amendment, remove the initial sequence listing, submit a substitute sequence listing and insert it into the specification. The paper copy and computer readable copy are also submitted. The computer readable copy of the substitute sequence listing and the attached paper copy are identical and meet the requirements of 37 CFR 1.821-1.825. No new matter has been added. In view of the enclosed substitute sequence submission, it is respectfully submitted that this objection is obviated.

No fee is believed to be due with respect to the filing of this amendment. If any additional fees are due, or an overpayment has been made, please charge, or credit, our Deposit Account No. 11-0171 for such sum.

If the Examiner has any questions regarding the present application, the Examiner is cordially invited to contact Applicants' attorney at the telephone number provided below.

Respectfully submitted,

William Dude

William D. Schmidt

Registration No.: 39,492 Attorney for Applicant(s)

Kalow & Springut LLP

Telephone No.: (212) 813-1600

T:\Patents\Applications\13092\20010604 reply to OA.doc